Ποια είναι η τιμή για Freeline Therapeutics Holdings plc (FRLN)

Η τιμή για Freeline Therapeutics Holdings plc (FRLN) είναι $6.48

Ποια είναι η κεφαλαιοποίηση αγοράς για Freeline Therapeutics Holdings plc (FRLN)

Η κεφαλαιοποίηση αγοράς για Freeline Therapeutics Holdings plc (FRLN) είναι $15.41M

Freeline Therapeutics Holdings plc (FRLN) Διαίρεση Μετοχών

Freeline Therapeutics Holdings plc is a biopharmaceutical company, currently in its clinical development phase, focused on creating groundbreaking gene therapies. These innovative treatments leverage adeno-associated virus (AAV) vector technology to tackle inherited, systemic, and severely debilitating genetic conditions. The company's leading therapeutic candidate, verbrinacogene setparvovec (FLT180a), is presently undergoing Phase 1/2 clinical trials for the management of hemophilia B in adult males. Furthermore, Freeline's pipeline features FLT190, which is also in Phase 1/2 clinical evaluation for treating Fabry disease, and FLT201, a gene therapy designed to target the liver for type 1 Gaucher disease, likewise progressing through Phase 1/2 trials. Beyond these specific programs, the company is actively pursuing research initiatives across a range of other systemic gene therapy indications. Freeline was established in 2015 and operates from its headquarters in Stevenage, United Kingdom.